Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 124 entries
Sorted by: Best Match Show Resources per page
EMG profiles of lower extremity muscles during cycling at constant workload and cadence.

Journal of electromyography and kinesiology : official journal of the International Society of Electrophysiological Kinesiology

Ryan MM, Gregor RJ.
PMID: 20719600
J Electromyogr Kinesiol. 1992;2(2):69-80. doi: 10.1016/1050-6411(92)90018-E.

Limited conclusions concerning the variability in EMG patterns during cycling can be made from available data in the literature because of methodological differences which include electrode placement and experimental design. The purpose of this study was to monitor EMG...

Cite
Ryan MM, Gregor RJ. EMG profiles of lower extremity muscles during cycling at constant workload and cadence. J Electromyogr Kinesiol. 1992;2(2):69-80doi: 10.1016/1050-6411(92)90018-E.
Ryan, M. M., & Gregor, R. J. (1992). EMG profiles of lower extremity muscles during cycling at constant workload and cadence. Journal of electromyography and kinesiology : official journal of the International Society of Electrophysiological Kinesiology, 2(2), 69-80. https://doi.org/10.1016/1050-6411(92)90018-E
Ryan, M M, and Gregor, R J. "EMG profiles of lower extremity muscles during cycling at constant workload and cadence." Journal of electromyography and kinesiology : official journal of the International Society of Electrophysiological Kinesiology vol. 2,2 (1992): 69-80. doi: https://doi.org/10.1016/1050-6411(92)90018-E
Ryan MM, Gregor RJ. EMG profiles of lower extremity muscles during cycling at constant workload and cadence. J Electromyogr Kinesiol. 1992;2(2):69-80. doi: 10.1016/1050-6411(92)90018-E. PMID: 20719600.
Copy Download .nbib Format: NLM
Early outcome of tetralogy of Fallot repair in the current era of management.

Journal of the Saudi Heart Association

Ismail SR, Kabbani MS, Najm HK, Abusuliman RM, Elbarbary M.
PMID: 23960595
J Saudi Heart Assoc. 2010 Apr;22(2):55-9. doi: 10.1016/j.jsha.2010.02.006. Epub 2010 Feb 24.

BACKGROUND: Traditional use of trans-annular patch (TAP) to release right ventricular outflow tract (RVOT) obstruction during tetralogy of Fallot (TOF) repair may lead to a harmful pulmonary regurgitation. Different approaches have been used to release RVOT obstruction and spare...

Cite
Ismail SR, Kabbani MS, Najm HK, et al. Early outcome of tetralogy of Fallot repair in the current era of management. J Saudi Heart Assoc. 2010;22(2):55-9doi: 10.1016/j.jsha.2010.02.006.
Ismail, S. R., Kabbani, M. S., Najm, H. K., Abusuliman, R. M., & Elbarbary, M. (2010). Early outcome of tetralogy of Fallot repair in the current era of management. Journal of the Saudi Heart Association, 22(2), 55-9. https://doi.org/10.1016/j.jsha.2010.02.006
Ismail, Sameh R, et al. "Early outcome of tetralogy of Fallot repair in the current era of management." Journal of the Saudi Heart Association vol. 22,2 (2010): 55-9. doi: https://doi.org/10.1016/j.jsha.2010.02.006
Ismail SR, Kabbani MS, Najm HK, Abusuliman RM, Elbarbary M. Early outcome of tetralogy of Fallot repair in the current era of management. J Saudi Heart Assoc. 2010 Apr;22(2):55-9. doi: 10.1016/j.jsha.2010.02.006. Epub 2010 Feb 24. PMID: 23960595; PMCID: PMC3727392.
Copy Download .nbib Format: NLM
Biomarkers and the Development of a Personalized Medicine Approach in Spinal Muscular Atrophy.

Frontiers in neurology

Kariyawasam DST, D'Silva A, Lin C, Ryan MM, Farrar MA.
PMID: 31481927
Front Neurol. 2019 Aug 19;10:898. doi: 10.3389/fneur.2019.00898. eCollection 2019.

Recent unprecedented advances in treatment for spinal muscular atrophy (SMA) enabled patients to access the first approved disease modifying therapy for the condition. There are however many uncertainties, regarding timing of treatment initiation, response to intervention, treatment effects and...

Cite
Kariyawasam DST, D'Silva A, Lin C, et al. Biomarkers and the Development of a Personalized Medicine Approach in Spinal Muscular Atrophy. Front Neurol. 2019;10:898doi: 10.3389/fneur.2019.00898.
Kariyawasam, D. S. T., D'Silva, A., Lin, C., Ryan, M. M., & Farrar, M. A. (2019). Biomarkers and the Development of a Personalized Medicine Approach in Spinal Muscular Atrophy. Frontiers in neurology, 10898. https://doi.org/10.3389/fneur.2019.00898
Kariyawasam, Didu S T, et al. "Biomarkers and the Development of a Personalized Medicine Approach in Spinal Muscular Atrophy." Frontiers in neurology vol. 10 (2019): 898. doi: https://doi.org/10.3389/fneur.2019.00898
Kariyawasam DST, D'Silva A, Lin C, Ryan MM, Farrar MA. Biomarkers and the Development of a Personalized Medicine Approach in Spinal Muscular Atrophy. Front Neurol. 2019 Aug 19;10:898. doi: 10.3389/fneur.2019.00898. eCollection 2019. PMID: 31481927; PMCID: PMC6709682.
Copy Download .nbib Format: NLM
Chitosan-MgO Nanocomposite: One Pot Preparation and Its Utility as an Ecofriendly Biocatalyst in the Synthesis of Thiazoles and [1,3,4]thiadiazoles.

Nanomaterials (Basel, Switzerland)

Riyadh SM, Khalil KD, Aljuhani A.
PMID: 30413060
Nanomaterials (Basel). 2018 Nov 08;8(11). doi: 10.3390/nano8110928.

A chitosan-MgO hybrid nanocomposite was prepared using a simple chemical precipitation method and characterized using Fourier transform spectroscopy (FTIR), elemental analysis (EDX), and scanning electron microscopy (SEM). The nanocomposite was served as a powerful ecofriendly basic catalyst under microwave...

Cite
Riyadh SM, Khalil KD, Aljuhani A. Chitosan-MgO Nanocomposite: One Pot Preparation and Its Utility as an Ecofriendly Biocatalyst in the Synthesis of Thiazoles and [1,3,4]thiadiazoles. Nanomaterials (Basel). 2018;8(11)doi: 10.3390/nano8110928.
Riyadh, S. M., Khalil, K. D., & Aljuhani, A. (2018). Chitosan-MgO Nanocomposite: One Pot Preparation and Its Utility as an Ecofriendly Biocatalyst in the Synthesis of Thiazoles and [1,3,4]thiadiazoles. Nanomaterials (Basel, Switzerland), 8(11), . https://doi.org/10.3390/nano8110928
Riyadh, Sayed M, et al. "Chitosan-MgO Nanocomposite: One Pot Preparation and Its Utility as an Ecofriendly Biocatalyst in the Synthesis of Thiazoles and [1,3,4]thiadiazoles." Nanomaterials (Basel, Switzerland) vol. 8,11 (2018). doi: https://doi.org/10.3390/nano8110928
Riyadh SM, Khalil KD, Aljuhani A. Chitosan-MgO Nanocomposite: One Pot Preparation and Its Utility as an Ecofriendly Biocatalyst in the Synthesis of Thiazoles and [1,3,4]thiadiazoles. Nanomaterials (Basel). 2018 Nov 08;8(11). doi: 10.3390/nano8110928. PMID: 30413060; PMCID: PMC6266359.
Copy Download .nbib Format: NLM
The different faces of the NLRP3 inflammasome in cutaneous Leishmaniasis: A review.

Cytokine

Kihel A, Hammi I, Darif D, Lemrani M, Riyad M, Guessous F, Akarid K.
PMID: 32807586
Cytokine. 2021 Nov;147:155248. doi: 10.1016/j.cyto.2020.155248. Epub 2020 Aug 15.

Cutaneous leishmaniasis (CL) is a vector-borne parasitic disease caused by Protozoa of the genus Leishmania. Clinical manifestations of this disease are the result of a complex interplay of diverse factors, including the genetic background and the immune status of...

Cite
Kihel A, Hammi I, Darif D, et al. The different faces of the NLRP3 inflammasome in cutaneous Leishmaniasis: A review. Cytokine. 2020;147:155248doi: 10.1016/j.cyto.2020.155248.
Kihel, A., Hammi, I., Darif, D., Lemrani, M., Riyad, M., Guessous, F., & Akarid, K. (2021). The different faces of the NLRP3 inflammasome in cutaneous Leishmaniasis: A review. Cytokine, 147155248. https://doi.org/10.1016/j.cyto.2020.155248
Kihel, Ayyoub, et al. "The different faces of the NLRP3 inflammasome in cutaneous Leishmaniasis: A review." Cytokine vol. 147 (2021): 155248. doi: https://doi.org/10.1016/j.cyto.2020.155248
Kihel A, Hammi I, Darif D, Lemrani M, Riyad M, Guessous F, Akarid K. The different faces of the NLRP3 inflammasome in cutaneous Leishmaniasis: A review. Cytokine. 2021 Nov;147:155248. doi: 10.1016/j.cyto.2020.155248. Epub 2020 Aug 15. PMID: 32807586.
Copy Download .nbib Format: NLM
The role of action potential changes in depolarization-induced failure of excitation contraction coupling in mouse skeletal muscle.

eLife

Wang X, Nawaz M, DuPont C, Myers JH, Burke SR, Bannister RA, Foy BD, Voss AA, Rich MM.
PMID: 34985413
Elife. 2022 Jan 05;11. doi: 10.7554/eLife.71588.

Excitation-contraction coupling (ECC) is the process by which electrical excitation of muscle is converted into force generation. Depolarization of skeletal muscle resting potential contributes to failure of ECC in diseases such as periodic paralysis, intensive care unit acquired weakness...

Cite
Wang X, Nawaz M, DuPont C, et al. The role of action potential changes in depolarization-induced failure of excitation contraction coupling in mouse skeletal muscle. Elife. 2022;11doi: 10.7554/eLife.71588.
Wang, X., Nawaz, M., DuPont, C., Myers, J. H., Burke, S. R., Bannister, R. A., Foy, B. D., Voss, A. A., & Rich, M. M. (2022). The role of action potential changes in depolarization-induced failure of excitation contraction coupling in mouse skeletal muscle. eLife, 11. https://doi.org/10.7554/eLife.71588
Wang, Xueyong, et al. "The role of action potential changes in depolarization-induced failure of excitation contraction coupling in mouse skeletal muscle." eLife vol. 11 (2022). doi: https://doi.org/10.7554/eLife.71588
Wang X, Nawaz M, DuPont C, Myers JH, Burke SR, Bannister RA, Foy BD, Voss AA, Rich MM. The role of action potential changes in depolarization-induced failure of excitation contraction coupling in mouse skeletal muscle. Elife. 2022 Jan 05;11. doi: 10.7554/eLife.71588. PMID: 34985413; PMCID: PMC8730720.
Copy Download .nbib Format: NLM
Correction: Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions.

Gene therapy

Riyad JM, Weber T.
PMID: 33911197
Gene Ther. 2021 Dec;28(12):771. doi: 10.1038/s41434-021-00252-y.

No abstract available.

Cite
Riyad JM, Weber T. Correction: Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions. Gene Ther. 2021;28(12):771doi: 10.1038/s41434-021-00252-y.
Riyad, J. M., & Weber, T. (2021). Correction: Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions. Gene therapy, 28(12), 771. https://doi.org/10.1038/s41434-021-00252-y
Riyad, Jalish M, and Weber, Thomas. "Correction: Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions." Gene therapy vol. 28,12 (2021): 771. doi: https://doi.org/10.1038/s41434-021-00252-y
Riyad JM, Weber T. Correction: Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions. Gene Ther. 2021 Dec;28(12):771. doi: 10.1038/s41434-021-00252-y. PMID: 33911197; PMCID: PMC8464619.
Copy Download .nbib Format: NLM
Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions.

Gene therapy

Riyad JM, Weber T.
PMID: 33658649
Gene Ther. 2021 Dec;28(12):683-696. doi: 10.1038/s41434-021-00243-z. Epub 2021 Mar 03.

In the last two decades, recombinant adeno-associated virus has emerged as the most popular gene therapy vector. Recently AAV gene therapy has been approved by the FDA for the treatment of two rare genetic disorders, namely the early childhood...

Cite
Riyad JM, Weber T. Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions. Gene Ther. 2021;28(12):683-696doi: 10.1038/s41434-021-00243-z.
Riyad, J. M., & Weber, T. (2021). Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions. Gene therapy, 28(12), 683-696. https://doi.org/10.1038/s41434-021-00243-z
Riyad, Jalish M, and Weber, Thomas. "Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions." Gene therapy vol. 28,12 (2021): 683-696. doi: https://doi.org/10.1038/s41434-021-00243-z
Riyad JM, Weber T. Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions. Gene Ther. 2021 Dec;28(12):683-696. doi: 10.1038/s41434-021-00243-z. Epub 2021 Mar 03. PMID: 33658649; PMCID: PMC8413391.
Copy Download .nbib Format: NLM
SARS-CoV-2 Alpha, Beta, and Delta variants display enhanced Spike-mediated syncytia formation.

The EMBO journal

Rajah MM, Hubert M, Bishop E, Saunders N, Robinot R, Grzelak L, Planas D, Dufloo J, Gellenoncourt S, Bongers A, Zivaljic M, Planchais C, Guivel-Benhassine F, Porrot F, Mouquet H, Chakrabarti LA, Buchrieser J, Schwartz O.
PMID: 34601723
EMBO J. 2021 Dec 15;40(24):e108944. doi: 10.15252/embj.2021108944. Epub 2021 Oct 25.

Severe COVID-19 is characterized by lung abnormalities, including the presence of syncytial pneumocytes. Syncytia form when SARS-CoV-2 spike protein expressed on the surface of infected cells interacts with the ACE2 receptor on neighboring cells. The syncytia forming potential of...

Cite
Rajah MM, Hubert M, Bishop E, et al. SARS-CoV-2 Alpha, Beta, and Delta variants display enhanced Spike-mediated syncytia formation. EMBO J. 2021;40(24):e108944doi: 10.15252/embj.2021108944.
Rajah, M. M., Hubert, M., Bishop, E., Saunders, N., Robinot, R., Grzelak, L., Planas, D., Dufloo, J., Gellenoncourt, S., Bongers, A., Zivaljic, M., Planchais, C., Guivel-Benhassine, F., Porrot, F., Mouquet, H., Chakrabarti, L. A., Buchrieser, J., & Schwartz, O. (2021). SARS-CoV-2 Alpha, Beta, and Delta variants display enhanced Spike-mediated syncytia formation. The EMBO journal, 40(24), e108944. https://doi.org/10.15252/embj.2021108944
Rajah, Maaran Michael, et al. "SARS-CoV-2 Alpha, Beta, and Delta variants display enhanced Spike-mediated syncytia formation." The EMBO journal vol. 40,24 (2021): e108944. doi: https://doi.org/10.15252/embj.2021108944
Rajah MM, Hubert M, Bishop E, Saunders N, Robinot R, Grzelak L, Planas D, Dufloo J, Gellenoncourt S, Bongers A, Zivaljic M, Planchais C, Guivel-Benhassine F, Porrot F, Mouquet H, Chakrabarti LA, Buchrieser J, Schwartz O. SARS-CoV-2 Alpha, Beta, and Delta variants display enhanced Spike-mediated syncytia formation. EMBO J. 2021 Dec 15;40(24):e108944. doi: 10.15252/embj.2021108944. Epub 2021 Oct 25. PMID: 34601723; PMCID: PMC8646911.
Copy Download .nbib Format: NLM
Multi-Omics Identifies Circulating miRNA and Protein Biomarkers for Facioscapulohumeral Dystrophy.

Journal of personalized medicine

Heier CR, Zhang A, Nguyen NY, Tully CB, Panigrahi A, Gordish-Dressman H, Pandey SN, Guglieri M, Ryan MM, Clemens PR, Thangarajh M, Webster R, Smith EC, Connolly AM, McDonald CM, Karachunski P, Tulinius M, Harper A, Mah JK, Fiorillo AA, Chen YW, Cooperative International Neuromuscular Research Group Cinrg Investigators.
PMID: 33228131
J Pers Med. 2020 Nov 19;10(4). doi: 10.3390/jpm10040236.

The development of therapeutics for muscle diseases such as facioscapulohumeral dystrophy (FSHD) is impeded by a lack of objective, minimally invasive biomarkers. Here we identify circulating miRNAs and proteins that are dysregulated in early-onset FSHD patients to develop blood-based...

Cite
Heier CR, Zhang A, Nguyen NY, et al. Multi-Omics Identifies Circulating miRNA and Protein Biomarkers for Facioscapulohumeral Dystrophy. J Pers Med. 2020;10(4)doi: 10.3390/jpm10040236.
Heier, C. R., Zhang, A., Nguyen, N. Y., Tully, C. B., Panigrahi, A., Gordish-Dressman, H., Pandey, S. N., Guglieri, M., Ryan, M. M., Clemens, P. R., Thangarajh, M., Webster, R., Smith, E. C., Connolly, A. M., McDonald, C. M., Karachunski, P., Tulinius, M., Harper, A., Mah, J. K., Fiorillo, A. A., Chen, Y. W., & Cooperative International Neuromuscular Research Group Cinrg Investigators. (2020). Multi-Omics Identifies Circulating miRNA and Protein Biomarkers for Facioscapulohumeral Dystrophy. Journal of personalized medicine, 10(4), . https://doi.org/10.3390/jpm10040236
Heier, Christopher R, et al. "Multi-Omics Identifies Circulating miRNA and Protein Biomarkers for Facioscapulohumeral Dystrophy." Journal of personalized medicine vol. 10,4 (2020). doi: https://doi.org/10.3390/jpm10040236
Heier CR, Zhang A, Nguyen NY, Tully CB, Panigrahi A, Gordish-Dressman H, Pandey SN, Guglieri M, Ryan MM, Clemens PR, Thangarajh M, Webster R, Smith EC, Connolly AM, McDonald CM, Karachunski P, Tulinius M, Harper A, Mah JK, Fiorillo AA, Chen YW, Cooperative International Neuromuscular Research Group Cinrg Investigators. Multi-Omics Identifies Circulating miRNA and Protein Biomarkers for Facioscapulohumeral Dystrophy. J Pers Med. 2020 Nov 19;10(4). doi: 10.3390/jpm10040236. PMID: 33228131; PMCID: PMC7711540.
Copy Download .nbib Format: NLM
Acetylcholine receptor subunit expression in Huntington's disease mouse muscle.

Biochemistry and biophysics reports

Simpson B, Rich MM, Voss AA, Talmadge RJ.
PMID: 34926838
Biochem Biophys Rep. 2021 Dec 05;28:101182. doi: 10.1016/j.bbrep.2021.101182. eCollection 2021 Dec.

Huntington's disease (HD) causes neurological impairments, as well as muscle dysfunction, including smaller neuromuscular junctions (NMJs). This study assessed the expression levels of the subunits of the nicotinic acetylcholine receptor (nAChR) in muscles of the R6/2 mouse model of...

Cite
Simpson B, Rich MM, Voss AA, et al. Acetylcholine receptor subunit expression in Huntington's disease mouse muscle. Biochem Biophys Rep. 2021;28:101182doi: 10.1016/j.bbrep.2021.101182.
Simpson, B., Rich, M. M., Voss, A. A., & Talmadge, R. J. (2021). Acetylcholine receptor subunit expression in Huntington's disease mouse muscle. Biochemistry and biophysics reports, 28101182. https://doi.org/10.1016/j.bbrep.2021.101182
Simpson, Briana, et al. "Acetylcholine receptor subunit expression in Huntington's disease mouse muscle." Biochemistry and biophysics reports vol. 28 (2021): 101182. doi: https://doi.org/10.1016/j.bbrep.2021.101182
Simpson B, Rich MM, Voss AA, Talmadge RJ. Acetylcholine receptor subunit expression in Huntington's disease mouse muscle. Biochem Biophys Rep. 2021 Dec 05;28:101182. doi: 10.1016/j.bbrep.2021.101182. eCollection 2021 Dec. PMID: 34926838; PMCID: PMC8649948.
Copy Download .nbib Format: NLM
Paediatric Code Stroke.

Journal of paediatrics and child health

Long E, Saw JTS, Davis C, Morgan C, Sheridan B, Monagle P, Ryan MM, Macdonald-Laurs E, Mackay MT.
PMID: 33870585
J Paediatr Child Health. 2021 Apr 19; doi: 10.1111/jpc.15509. Epub 2021 Apr 19.

No abstract available.

Cite
Long E, Saw JTS, Davis C, et al. Paediatric Code Stroke. J Paediatr Child Health. 2021;doi: 10.1111/jpc.15509.
Long, E., Saw, J. T. S., Davis, C., Morgan, C., Sheridan, B., Monagle, P., Ryan, M. M., Macdonald-Laurs, E., & Mackay, M. T. (2021). Paediatric Code Stroke. Journal of paediatrics and child health, . https://doi.org/10.1111/jpc.15509
Long, Elliot, et al. "Paediatric Code Stroke." Journal of paediatrics and child health vol. (2021). doi: https://doi.org/10.1111/jpc.15509
Long E, Saw JTS, Davis C, Morgan C, Sheridan B, Monagle P, Ryan MM, Macdonald-Laurs E, Mackay MT. Paediatric Code Stroke. J Paediatr Child Health. 2021 Apr 19; doi: 10.1111/jpc.15509. Epub 2021 Apr 19. PMID: 33870585.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 124 entries